NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1051 coverAUTOIMMUNE DISEASES AND TREATMENT: Organ-Specific and Systemic Disorders Volume 1051 published June 2005
Ann. N.Y. Acad. Sci. 1051: 390–403 (2005). doi: 10.1196/annals.1361.081
Copyright © 2005 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by BRUNER, B. F.
Articles by JAMES, J. A.
Search for Related Content
PubMed
PubMed Citation
Articles by BRUNER, B. F.
Articles by JAMES, J. A.
Humoral Antigenic Targets of the Ribosomal P0 Lupus Autoantigen Are Not Limited to the Carboxyl Region

BENJAMIN F. BRUNERa,b, DONNY M. WYNNa,b, MORRIS REICHLINa, JOHN B. HARLEYa,b AND JUDITH A. JAMESa,b

aArthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA
bDepartments of Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA

Address for correspondence: Judith A. James, M.D., Ph.D., Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104. Voice: 405-271-4987; fax: 405-271-7063. jamesj{at}omrf.ouhsc.edu

Autoantibodies binding the ribosomal P phosphoproteins are highly specific for systemic lupus erythematosus (SLE) and can be found in precipitating levels in approximately 15% of these patients. Anti-ribosomal P antibodies are directed against three proteins, and the primary autoimmune target of this response has been described as a common 22-amino acid sequence. Sera from 31 anti-ribosomal P immunodiffusion-positive SLE patients were tested for C-terminal P-peptide reactivity by ELISA. Sera from three patients (9.7%) were negative for the peptide ELISA, despite having anti-ribosomal P by immunodiffusion and Western blot. In addition, inhibition experiments showed that the common P-peptide response accounts for a variable amount of anti-ribosomal P0 reactivity (52-89% of the response dependent upon the patient serum). Based upon these findings, fine-specificity sequential humoral epitope mapping of ribosomal P0 was performed. Several common sequential antigenic targets were defined dispersed throughout the molecule. The most commonly targeted epitopes included RDMLLANKVPAAARA (amino acids 99-113, 11 of 12 patients reactive) and QALGITTKISRGT (amino acids 139-151, 9 of 12 patients reactive). This study confirms that the P22 ribosomal peptide is commonly targeted in SLE and accounts for a variable percentage of the anti-ribosomal P response. Additional anti-ribosomal P humoral epitopes are described.

Key Words: autoantibodies • lupus • anti-ribosomal P • ribosomal P0 • epitope






footerLeft footerRight